首页> 美国卫生研究院文献>BMC Infectious Diseases >Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany
【2h】

Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany

机译:德国成人和儿童抵抗小儿麻痹症病毒1型CHAT和Sabin(LSc-2ab)的免疫状况

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundIn October 2007, the working group CEN/TC 216 of the European Committee for standardisation suggested that the Sabin oral poliovirus vaccine type 1 strain (LSc-2ab) presently used for virucidal tests should be replaced by another attenuated vaccine poliovirus type 1 strain, CHAT. Both strains were historically used as oral vaccines, but the Sabin type 1 strain was acknowledged to be more attenuated. In Germany, vaccination against poliomyelitis was introduced in 1962 using the oral polio vaccine (OPV) containing Sabin strain LSc-2ab. The vaccination schedule was changed from OPV to an inactivated polio vaccine (IPV) containing wild polio virus type 1 strain Mahoney in 1998. In the present study, we assessed potential differences in neutralising antibody titres to Sabin and CHAT in persons with a history of either OPV, IPV, or OPV with IPV booster.
机译:背景技术2007年10月,欧洲标准化委员会CEN / TC 216工作组建议将目前用于杀伤性测试的萨宾口腔脊髓灰质炎病毒1型菌株(LSc-2ab)换成另一种减毒的脊髓灰质炎1型脊髓灰质炎疫苗。历史上,这两种菌株都用作口服疫苗,但是公认Sabin 1型菌株减毒性更高。在德国,1962年使用含有Sabin菌株LSc-2ab的口服脊髓灰质炎疫苗(OPV)引入了针对小儿麻痹症的疫苗。在1998年,疫苗接种时间表从OPV改为包含脊髓灰质炎1型野生脊髓灰质炎病毒株的灭活脊髓灰质炎疫苗(IPV)。在本研究中,我们评估了既往有既往史或既往史的人中和Sabin和CHAT抗体滴度的潜在差异OPV,IPV或带IPV增强器的OPV。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号